Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade
- 1 November 2015
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 194 (5) , 1264-1270
Abstract
We examined the clinical significance of long-term serum testosterone monitoring to predict the prognosis of patients with prostate cancer treated with combined androgen blockade. We retrospectively analyzed the records of 225 patients who underwent combined androgen blockade as first line therapy for prostate cancer. The prognostic values of testosterone and other clinical factors were evaluated with respect to prostate specific antigen progression-free and overall survival. Median patient age was 73.0 years, median prostate specific antigen was 42.6 ng/ml and median followup was 45.8 months. No variable associated with testosterone was predictive of progression-free survival. With regard to overall survival on univariate analysis nadir testosterone less than 16 ng/dl (p = 0.0190), less than 20 ng/dl (p = 0.0020) and less than 32 ng/dl (p = 0.0146) were significant together with other clinical factors. In contrast, nadir testosterone less than 8 and less than 12 ng/dl were not significant. Multivariate analysis showed that nadir testosterone less than 20 ng/dl was the significant prognostic factor (p = 0.0048). In addition, time to nadir testosterone was about 1 year (11.3 months). Patients were divided into rapid and slow types based on time to testosterone less than 20 ng/dl before and after 6 months, respectively. No significant difference in overall survival was observed between the 2 types. The current results suggest that the critical factor for prognosis was not a rapid decrease but whether nadir testosterone achieved a level of less than 20 ng/dl. Nadir testosterone 20 ng/dl was the most significant cutoff level for overall survival in Japanese patients with prostate cancer treated with combined androgen blockade.Keywords
This publication has 19 references indexed in Scilit:
- The Relationship between Total Testosterone Levels and Prostate Cancer: A Review of the Continuing ControversyJournal of Urology, 2015
- Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade?International Journal of Urology, 2014
- Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate CancerClinical Genitourinary Cancer, 2013
- Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass SpectrometryJournal of Urology, 2012
- Low Testosterone and Risk of Biochemical Recurrence and Poorly Differentiated Prostate Cancer at Radical ProstatectomyUrology, 2008
- Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation TherapyJournal of Urology, 2007
- The Importance of Testosterone Control in Prostate CancerEuropean Urology Supplements, 2007
- TESTOSTERONE AS A PREDICTOR OF PATHOLOGICAL STAGE IN CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2005
- High‐grade prostate cancer is associated with low serum testosterone levelsThe Prostate, 2001
- IS LOW SERUM FREE TESTOSTERONE A MARKER FOR HIGH GRADE PROSTATE CANCER?Journal of Urology, 2000